

Continuation of Serial No. 10/030,187

Remarks

This application seeks protection for certain novel compounds that are inhibitors of the serine protease, Factor Xa, and are useful for the treatment of thrombotic disorders. It is a continuation of the national stage of an international application, the claims of which were drafted in accordance with international practice. The claims in the parent application have been limited to one specific compound.

Applicants now wish to amend the application to bring it into conformity with United States patent practice. It is believed that these amendments will place the application in order for allowance.

Claims 13 to 18, 20, 25, 28, 29, 31 and 32 have been cancelled, without prejudice.

Claims 4 to 6, 9 to 12, 19, 21 to 24, 27 and 33 have been rewritten to remove improper claim dependencies.

Claim 1 has been amended by incorporating definitions from the specification for:-

R₂: page 23, line 20 to page 25, line 7;

R₁: page 25, line 33 to page 26, line 15;

R_{1j}: page 26, lines 16 to 30;

-X-X-: page 9, lines 27-28 and Claim 13;

Y: page 9, line 34 and Claim 14;

Cy: page 15, lines 16 to 24 and Claim 15; and

R_{3a}: page 16, line 6 to page 17, line 16 and Claim 18.

Claim 2 has been amended to remove definitions also found in Claim 1. Claim 2 has been further amended by inserting the value "piperidin-4-yl (which may bear a 1-methyl substituent,)" in the definition of CH_{Re}R_f before "or indan-2-yl". Basis for this amendment may be found in the corresponding passage at page 8, lines 22 to 23 of the specification. It has further been amended by incorporating the subject matter of Claims 16 and 20.

Continuation of Serial No. 10/030,187

Claim 7 has been amended by inserting a definition for L, based upon page 11, line 16.

Claim 9 now incorporates the definition for R₂ at page 26, line 31 to page 28, line 10 of the specification.

Claim 10 now incorporates the definition for R₂ at page 28, line 11 to page 29, line 29 of the specification.

In Claim 21, minor grammatical corrections have been made.

Claim 26 has been amended to exclude the compound 1-(indole-6-carbonyl-D-phenylglycinyl)-4-(1-methylpiperidin-4-yl)piperazine, which is claimed specifically in the parent application.

Claim 30 has been amended in a manner consistent with the amendment made in the method claim in the parent application. Support may be found at page 2, lines 21 to 26 of the specification.

Claim 33 has been amended to introduce a definition for Cy, by referring back to Claims 1, 21 and 22.

New Claim 34 is based upon Claim 25.

New Claim 35 is based upon Claim 27.

New Claim 36 is based upon Claim 30.

New Claim 37 is also based upon Claim 30, but is limited to a method of treating a human body.